LSN's Sourcing & Ranking Service (SRS) provides clients with an opportunity to quickly source, vet, rank and engage with partners that are licensing global technology assets.
Click to see investors that are a fit for your product and stage of development
Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you
Click here if you want to receive free, targeted early stage dealflow for your life science investment firm
RESI is heading to Toronto for the third time, and LSN will soon be reviewing applications to the RESI Innovation Challenge. This is an opportunity for entrepreneurs to win a display space at RESI and make their mark at Toronto Health Innovation Week. You have until Friday March 2nd to apply - that's tomorrow!
The RESI Innovation Challenge covers startups in therapeutics, medtech, diagnostics and healthcare IT from around the globe. All applicants will be vetted based not only on the quality of the company's scientific work, but also on the strength of the management team and how well-positioned the company is to receive investment...
Within the last few months, China has been formally rolling out their new CFDA regulations that have given startups and new technology developers in China all sorts of benefits. These benefits include allowing the submission of data from clinical trial sites outside of China, allowing more Chinese hospitals to run trials, and allowing drug makers who are waiting for the green light on a safety study to go ahead if they haven't heard back from the CFDA within 60 days.
All these regulation changes have seen a big boom to China's biotech innovations. In fact, many Taiwanese companies have seen this regulatory shift as an opportunity to get into the Chinese market. Companies such as Taiwan Liposome (TLC) have started joint ventures with Chinese investors in order to run trials and commercialize their products in China. With the ability to submit their clinical trial data from Taiwan and start their new trials more quickly in China, many of these companies expect to see NDA filings for their assets by the end of the year...
Life Science Nation (LSN) just revamped its LinkedIn profile in an effort to help life science startups engage with potential investors! With the growing impact of social media, we aim to create another avenue to build connections with early-stage life science players and offer content relevant to our growing community.
On the primary LSN profile, we will post the hottest investor mandates from our LSN Database, latest news about the life science industry, and updates on the Redefining Early Stage Investment (RESI) conference series.
LSN has also created a separate RESI Conference group on LinkedIn to help past and new attendees stay connected with one another. Through this channel, members can promote their companies, announce updates on the development of their technologies, build relationships with other like-minded members, and collectively move the needle in the life sciences.
We hope you will connect with us and help us build a startup community that can make an impact on the life science industry!
Life Science Investor Mandates
Within the last few months, China has been formally rolling out their new CFDA regulations that have given startups and new technology developers in China all sorts of benefits. These benefits include allowing the submission of data from clinical trial sites outside of China, allowing more Chinese hospitals to run trials, and allowing drug makers who are waiting for the green light on a safety study to go ahead if they haven't heard back from the CFDA within 60 days.
Life Science Nation (LSN) just revamped its LinkedIn profile in an effort to help life science startups engage with potential investors! With the growing impact of social media, we aim to create another avenue to build connections with early-stage life science players and offer content relevant to our growing community.
